{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"229.7","value":"947"},{"groupId":"OG001","spread":"127.2","value":"1600"},{"groupId":"OG002","spread":"51.6","value":"2180"},{"groupId":"OG003","spread":"88.8","value":"1970"},{"groupId":"OG004","spread":"63.5","value":"2550"},{"comment":"calculation not performed for a single participant.","groupId":"OG005","spread":"NA","value":"NA"},{"groupId":"OG006","spread":"77.7","value":"1900"},{"groupId":"OG007","spread":"27.6","value":"2150"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"description":"The area under the plasma concentration-curve from time 0 to time infinity (AUCinf) was estimated using the linear trapezoidal method\n\nPK samples obtained on the following schedule:\n\nPhase 1b Continuous Dosing, Cycles 1 and 2: Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 8 hours post-dose plus pre-dose on Day 2 Phase 1b Step-up Dosing, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 Phase 2, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who were administered 180 mg oprozomib tablets.","id":"OG000","title":"180 mg Oprozomib Tablet"},{"description":"Participants who were administered 210 mg oprozomib tablets.","id":"OG001","title":"210 mg Oprozomib Tablet"},{"description":"Participants who were administered 240 mg oprozomib tablets.","id":"OG002","title":"240 mg Oprozomib Tablet"},{"description":"Participants who were administered 270 mg oprozomib tablets.","id":"OG003","title":"270 mg Oprozomib Tablet"},{"description":"Participants who were administered 300 mg oprozomib tablets.","id":"OG004","title":"300 mg Oprozomib Tablet"},{"description":"Participants who were administered 150 mg extended release oprozomib tablets.","id":"OG005","title":"150 mg Oprozomib ER Tablet"},{"description":"Participants who were administered 300 mg extended release oprozomib tablets.","id":"OG006","title":"300 mg Oprozomib ER Tablet"},{"description":"Participants who were administered 330 mg extended release oprozomib tablets.","id":"OG007","title":"330 mg Oprozomib ER Tablet"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Day 1","title":"Pharmacokinetic (PK) Parameter for Oprozomib, Tablet and ER Formulation: Area Under the Curve From Time 0 to Time Infinity (AUCinf) on Cycle 1, Day 1","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}